199 related articles for article (PubMed ID: 25912588)
1. Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
Peng DF; Tang SY; Hu YJ; Chen J; Peng X; Huang Q
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1264-71. PubMed ID: 25912588
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Tang SY; Peng DF; Hu YJ; Chen J
Eur Rev Med Pharmacol Sci; 2015; 19(5):759-66. PubMed ID: 25807427
[TBL] [Abstract][Full Text] [Related]
3. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
4. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Ruggenenti P; Trillini M; P Barlovic D; Cortinovis M; Pisani A; Parvanova A; Iliev IP; Ruggiero B; Rota S; Aparicio MC; Perna A; Peraro F; Diadei O; Gaspari F; Carrara F; Stucchi N; Martinetti D; Janez A; Gregoric N; Riccio E; Bossi AC; Trevisan R; Manunta P; Battaglia G; David S; Aucella F; Belviso A; Satta A; Remuzzi G;
Diabetes Obes Metab; 2019 May; 21(5):1177-1190. PubMed ID: 30793466
[TBL] [Abstract][Full Text] [Related]
5. [Effects of benazepril combined with valsartan on congestive heart failure].
Ye JF; Liu DS
Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1441-2, 1447. PubMed ID: 16305977
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799
[TBL] [Abstract][Full Text] [Related]
7. Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy.
Jin H; Zhang HN; Hou XL; Zhang B; Wu J; Zhang HB
Eur Rev Med Pharmacol Sci; 2016; 20(1):174-9. PubMed ID: 26813471
[TBL] [Abstract][Full Text] [Related]
8. [Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension].
Guo LL; Li M; Wang AH
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1761-3. PubMed ID: 22027785
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
10. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Ke YS; Cao H; Yang T
Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
[TBL] [Abstract][Full Text] [Related]
12. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
[TBL] [Abstract][Full Text] [Related]
14. [Effect of treatment in 39 patients with diabetic nephropathy by safflor yellow and benazepril in combination].
Guo DZ; Wang YH; Chen ZQ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Apr; 28(4):360-3. PubMed ID: 18543495
[TBL] [Abstract][Full Text] [Related]
15. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone.
Pool J; Kaihlanen P; Lewis G; Ginsberg D; Oparil S; Glazer R; Messerli FH
J Hum Hypertens; 2001 Jul; 15(7):495-8. PubMed ID: 11464260
[TBL] [Abstract][Full Text] [Related]
16. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Esnault VL; Ekhlas A; Delcroix C; Moutel MG; Nguyen JM
J Am Soc Nephrol; 2005 Feb; 16(2):474-81. PubMed ID: 15615822
[TBL] [Abstract][Full Text] [Related]
17. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial.
Menne J; Farsang C; Deák L; Klebs S; Meier M; Handrock R; Sieder C; Haller H
J Hypertens; 2008 Sep; 26(9):1860-7. PubMed ID: 18698222
[TBL] [Abstract][Full Text] [Related]
18. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Hou FF; Xie D; Zhang X; Chen PY; Zhang WR; Liang M; Guo ZJ; Jiang JP
J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
[TBL] [Abstract][Full Text] [Related]
19. Impact of N-acetylcysteine on endothelial function, B-type natriuretic peptide and renal function in patients with the cardiorenal syndrome: a pilot cross over randomised controlled trial.
Camuglia AC; Maeder MT; Starr J; Farrington C; Kaye DM
Heart Lung Circ; 2013 Apr; 22(4):256-9. PubMed ID: 23219310
[TBL] [Abstract][Full Text] [Related]
20. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
Zhang GH; Hou FF; Zhang X; Liu QF
Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
